PBYI News and Press, Puma Biotechnology Inc From 05/06/21

Puma Biotechnology, Inc. (PBYI) Q1 2021 Earnings Conference Call May 06, 2021, 4:30 PM ET Company Participants Mariann Ohanesian - Senior Director, IR Alan Auerbach - Founder, Chairman, President, CEO & Secretary Jeff Ludwig - Chief Commercial Officer Maximo Nougues - CFO & Principal ...

Puma Biotechnology (PBYI): Q1 Non-GAAP EPS of $0.55 beats by $0.21; GAAP EPS of $0.40 beats by $0.40.Revenue of $98.2M (+91.8% Y/Y) beats by $31.32M.Shares +3.3%.Press Release For further details see: Puma Biotechnology EPS beats by $0.21, beats on revenue

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced financial results for the first quarter ended March 31, 2021. Unless otherwise stated, all comparisons are for the first quarter of 2021 compared to the first quarter of 2020. Product revenue, net consis...

Puma's sales fell 17% last year and the company continued burning cash. Four years into the launch of Nerlynx, market penetration remains below expectations. Recent trial updates provide little hope of changing the narrative around Nerlynx. For further details see: Puma ...

Celcuity (CELC) announces a clinical trial collaboration with the MD Anderson Cancer Center, Novartis AG (NVS), and Puma Biotechnology (PBYI), to conduct a Phase II clinical trial to evaluate the efficacy and safety of two targeted therapies in certain patients with metastatic HER2-...

The following slide deck was published by Puma Biotechnology, Inc. in conjunction with this event. For further details see: Puma Biotechnology (PBYI) Presents At Barclays Global Healthcare Virtual Conference

Phase III trial patient enrollment for balixafortide completed in Q4 2020 despite COVID-19. Results expected for ORR and PFS in Q2 and Q4 2021 respectively Exclusive licensing agreement for balixafortide in China with Fosun Pharma Clinical Trial Authorizati...

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that Alan H. Auerbach, Chairman, Chief Executive Officer, President and Founder of Puma, will provide an overview of the Company at the Barclays Global Healthcare Conference, which will be held virtually fro...

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that Alan H. Auerbach, Chairman, Chief Executive Officer, President and Founder of Puma, will provide an overview of the Company at the H.C. Wainwright Global Life Sciences Conference, which will be held vir...

Puma Biotechnology (PBYI) and CANbridge Pharmaceuticals have agreed to terminate their 2018 license agreement, in which Puma granted CANbridge exclusive rights to develop and commercialize NERLYNX (neratinib) in Greater China, and to settle their arbitration related to the license agreem...